Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Gundersen

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Scientific Reports|November 17, 2022
Aquaculture rearing systems induce no legacy effects in Atlantic cod larvae or their rearing water bacterial communitiesMadeleine S Gundersen, Olav Vadstein, Peter De Schryver, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer GroupS Gundersen, S Kvinnsland, O Klepp, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1992
Droloxifene--a new anti-estrogen. A phase II study in advanced breast cancerH Haarstad, S Gundersen, E Wist, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1986
Weekly adriamycin versus VAC in advanced breast cancer. A randomized trialS Gundersen, S Kvinnsland, O Klepp, et al.
ISME Communications|November 8, 2023
The effect of periodic disturbances and carrying capacity on the significance of selection and drift in complex bacterial communitiesMadeleine S Gundersen, Ian Arthur Morelan, Tom Andersen, et al.
Breast Cancer Research and Treatment|January 1, 1995
Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: a randomized studyS Gundersen, E Hannisdal, J A Søreide, et al.
Journal of the National Cancer Institute|September 7, 1988
Phase II study of intravenous menogaril in patients with advanced breast cancerC Sessa, S Gundersen, W ten Bokkel Huinink, et al.
The Journal of Endocrinology|August 1, 1995
Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancerJ Geisler, H Haarstad, S Gundersen, et al.
Cancer|February 19, 2000
The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 yearsW Reed, E Hannisdal, P J Boehler, et al.
Acta Oncologica (Stockholm, Sweden)|September 22, 1998
Influence of droloxifene on metastatic breast cancer as first-line endocrine treatmentH Haarstad, P E Lønning, S Gundersen, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Scientific Reports|November 17, 2022
Aquaculture rearing systems induce no legacy effects in Atlantic cod larvae or their rearing water bacterial communitiesMadeleine S Gundersen, Olav Vadstein, Peter De Schryver, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Chemotherapy with or without high-dose medroxyprogesterone acetate in oestrogen-receptor-negative advanced breast cancer. Norwegian Breast Cancer GroupS Gundersen, S Kvinnsland, O Klepp, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 1992
Droloxifene--a new anti-estrogen. A phase II study in advanced breast cancerH Haarstad, S Gundersen, E Wist, et al.
European Journal of Cancer & Clinical Oncology|December 1, 1986
Weekly adriamycin versus VAC in advanced breast cancer. A randomized trialS Gundersen, S Kvinnsland, O Klepp, et al.
ISME Communications|November 8, 2023
The effect of periodic disturbances and carrying capacity on the significance of selection and drift in complex bacterial communitiesMadeleine S Gundersen, Ian Arthur Morelan, Tom Andersen, et al.
Breast Cancer Research and Treatment|January 1, 1995
Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: a randomized studyS Gundersen, E Hannisdal, J A Søreide, et al.
Journal of the National Cancer Institute|September 7, 1988
Phase II study of intravenous menogaril in patients with advanced breast cancerC Sessa, S Gundersen, W ten Bokkel Huinink, et al.
The Journal of Endocrinology|August 1, 1995
Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancerJ Geisler, H Haarstad, S Gundersen, et al.
Cancer|February 19, 2000
The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 yearsW Reed, E Hannisdal, P J Boehler, et al.
Acta Oncologica (Stockholm, Sweden)|September 22, 1998
Influence of droloxifene on metastatic breast cancer as first-line endocrine treatmentH Haarstad, P E Lønning, S Gundersen, et al.
Pageof 7